SLC5A2 and type 2 diabetes mellitus: Several studies continue to examine the cardiovascular effects of metformin, and several prospective studies with cardiovascular endpoints are ongoing, notably SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes (SMARTEST) (NCT03982381) [95,96], Metformin and Prevention of Cardiovascular Events in Patients With Acute Myocardial Infarction and Prediabetes (MIMET) (NCT05182970) [97,98], DANHEART (H-HeFT and Met-HeFT) (NCT03514108) [99,100], and Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes (VA-IMPACT) (NCT02915198) [101].